Wockhardt Ltd Q3 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/pftxv588pxmts08fo87g572l.pdf

Key Takeaways


The Turnaround Narrative

Dr. Habil Khorakiwala: "I personally feel we are at a very important point in the life of the company and we are at a turning point stage. We went through challenging times in the past. But where we are moving forward is opportunities, opportunities and opportunities."

US Business Restructuring


WCK 5222: The High-Stakes Antibiotic Asset

Dr. Habil Khorakiwala: "There are no drugs in the market which comes anywhere near 5222. At the same time, we don't see any drug in the clinical trial which are there in covering the spectrum."

Serum Institute Vaccine Partnership


Base Business & Biosimilars

Dr. Murtaza Khorakiwala: "We believe that being integrated right from beginning to ending with R&D, manufacturing, regulatory, trend devices and having our own IP and commercial organization... it provides us a very sustainable competitive advantage in terms of cost, in terms of value creation."

Pipeline Beyond 5222


Guidance & Commitments

CommitmentSpecificsTimeline
US business profitabilityUS business will turn profitable "definitely"By 2025
Organization PBT positiveOrganization working towards being PBT positiveIn two years' time
WCK 5222 Phase 3 completionComplete global Phase 3 trialNext 12 to 18 months
WCK 5222 market entrySeek approval and be in markets (US, Europe, China, India)Sometime in 2025
WCK 5222 trial fundingFund ~USD 30 mn balance via alternate funding, debt, asset monetization; not from operational cash flowDuring trial period
Emrok emerging market approvalsReceive approval in eight emerging marketsNext 6 to 9 months
4873 India Phase 3 completionConclude Phase 3 trial in IndiaSometime in 2024
4873 India launchFile and launch in India2025
Insulin Aspart India launchFile and launch in India2025
Serum vaccine manufacturing startInitiate manufacturing of two identified vaccines after exhibit batches and regulatory approvalWithin next 12 months
UK product filingsFile another 24 products2023 and 2024
Biologics revenue mixIncrease biologics contribution from 20% to 30% of businessNext two to three years

Key Metrics

MetricQ3 FY23
Revenue₹699 cr, +20% QoQ from ₹578 cr in Q1FY23
EBITDA₹59 cr, positive for second consecutive quarter; ₹39 cr in Q2FY23
Operating cash flow₹95 cr positive
External debt~₹600 cr, reduced from ₹3,200 cr over five years
External debt to equity0.16, reduced from 0.96 over five years
Promoter commitment (quasi-equity)₹700 cr, improved from ₹208 cr
Promoter loan converted to equity₹500 cr
Rights issue proceeds₹250 cr from investors
Debt reduction in Q3₹109 cr
Promoter infusion in Q3₹71 cr
Cash balance₹217 cr at quarter end, from ₹221 cr opening
UK business revenue₹223 cr, up from ₹208 cr in same quarter last year
UK market share increase>1% in covered market
India business revenue₹175 cr, up from ₹150 cr in Q2FY23
India business 9-month revenue₹483 cr, up from ₹450 cr
Diabetes business 9-month growth>20%
Emerging markets revenue₹148 cr, up from ₹117 cr in earlier quarters
Biologics revenue share~20% of total revenue
Emrok and Emrok O annual sales>₹30 cr
US restructuring expected savings$12 million in losses
US third-party manufacturing gross margin~40%
Serum agreement reserved capacity15 crore doses per year for 15 years
Serum agreement profit share51:49 in favor of Wockhardt
Serum agreement upfront contribution£1 crore
WCK 5222 phase 3 trial completion~20% of patients completed
WCK 5222 additional investment required~$30 million
R&D spend target8% to 9% of revenue
UK product filings since 2020>23 filed, 24 more planned for 2023-2024
India and UK launches planned FY24-2514 in India, 25 in UK